Drugs / ISMIDENON
ISMIDENON
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03764462 | Dec 2018 → Jan 2019 | osteoporosis | Addpharma Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04478279 | Jul 2020 → Dec 2026 expected | brain cancer, breast cancer, glioblastoma, metastatic melanoma +1 | Sapience Therapeutics | Active not recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01332695 | Apr → Dec 2011 | essential tremor | Sonexa Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00842816 | Feb 2009 → May 2011 | Alzheimer disease | Sonexa Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00842673 | Feb 2009 → Sep 2010 | Alzheimer disease | Sonexa Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISMIDENON | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297437 ↗ |
| Known as | AD-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03764462 ↗ |
| Known as | ST101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00842816 ↗ |
| Known as | ZSET-1446 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297437 ↗ |
| Modality | Small molecule | — CHEMBL4297437 ↗ |
| Route | Oral | “tablets for oral administration” NCT01332695 ↗ |